Pharma

Your Article Summary

See Latest Articles

Elan and Transition Therapeutics Receive Key Patent for Alzheimers Disease Treatment with ELND005
Elan, 04/24/09

Elan Corporation, plc and Transition Therapeutics Inc. announced the United States Patent and Trademark Office issued US patent number 7,521,481 on April 2009. The patent is entitled “Methods of Preventing, Treating and Diagnosing Disorders of Protein Aggregation,” and generally claims methods for treating Alzheimer's disease comprising administering scyllo-inositol. The patent will expire in the year 2025 or later due to any patent term extensions.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals